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Background: Lithium has proven suicide preventing effects in the long-term treatment of patients with affective
disorders. Clinical evidence from case reports indicate that this effect may occur early on at the beginning of lithium
treatment. The impact of lithium treatment on acute suicidal thoughts and/or behavior has not been systematically
studied in a controlled trial. The primary objective of this confirmatory study is to determine the association between
lithium therapy and acute suicidal ideation and/or suicidal behavior in inpatients with a major depressive episode
(MDE, unipolar and bipolar disorder according to DSM IV criteria). The specific aim is to test the hypothesis that
lithium plus treatment as usual (TAU), compared to placebo plus TAU, results in a significantly greater decrease
in suicidal ideation and/or behavior over 5 weeks in inpatients with MDE.
Methods/Design: We initiated a randomized, placebo-controlled multicenter trial. Patients with the diagnosis
of a moderate to severe depressive episode and suicidal thoughts and/or suicidal behavior measured with the
Sheehan-Suicidality-Tracking Scale (S-STS) will be randomly allocated to add lithium or placebo to their treatment as
usual. Change in the clinician administered S-STS from the initial to the final visit will be the primary outcome.
Discussion: There is an urgent need to identify treatments that will acutely decrease suicidal ideation and/or suicidal
behavior. The results of this study will demonstrate whether lithium reduces suicidal ideation and behavior within
the first 5 weeks of treatment.
Trial registration: ClinicalTrials.gov identifier: NCT02039479
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creativecommons.org/publicdomain/zero/1.0/Epidemiological studies have led to more information
about risk and protective factors in general population
and in patients with psychiatric diseases. As it is indi-
cated in the first report on suicide prevention (WHO
2014 [1]) many universal, selected and indicated strat-
egies have been implemented worldwide to improve the
knowledge about suicide, increase the access to health
care professionals, train the gatekeepers and therefore
lead to an improvement in identification and manage-
ment of people at risk. Twenty eight countries have
established national suicide prevention programs dedicatedarticle distributed under the terms of the Creative Commons Attribution License
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need to expand suicide prevention research and anti-
suicidal strategies. Lithium treatment has been a popular
research avenue given its often replicated anti-suicidal
effects and different effects on the human body.
For example, studies have investigated the influence of
lithium therapy on neuroprotection [2], inflammation
[3], genetic changes [4] and its anti-suicidal properties.
Lithium is approved in International Guidelines for the
maintenance treatment of bipolar disorder [5–7] and
has shown to be effective in prevention of depressive
and manic episodes. Long-term treatment with lithium
has been shown to be effective in preventing both sui-
cide and attempted suicide in patients with unipolar and
bipolar depression. Further, lithium appears to be more
effective in reducing suicide compared to other pharma-
cological treatments effective in preventing mood epi-
sodes (e.g. valproate) as well as compared to placebo.
One piece of evidence derives from randomized con-
trolled trials investigating the mood-stabilizing effect of
lithium. More specific information, however, has been
gained from the careful analysis of cohorts of well docu-
mented patients having received lithium over many years
under constant systematic monitoring (for a comprehen-
sive overview please see Lewitzka et al., submitted [8]).
As patients with mood disorders have a 30-fold greater
risk of suicide compared to the general population, it is
of great importance to systematically study the acute
effects of lithium in a controlled setting.
So far little is known about the mechanism behind this
effect. Neurobiological research has focused on lithium’s
influence on neurotransmitters such as serotonin [9]
or noradrenalin and dopamine [10]. Lithium’s influ-
ences on the cortisol stress hormone system [11], the
γ-aminobutyric-acid [12], second messenger systems
such as the inositol metabolism and glycogen syn-
thase kinase 3 have also been investigated [13]. Lithium
has demonstrated to have an effect on impulsivity and ag-
gression via several pathways within the nerve cell [14, 15]
which is discussed as one of the underlying mechanisms
behind the anti-suicidal efficacy.
As suicide research has to deal with specific methodo-
logical difficulties the design and development of study
protocols needs to be cautious. Ethical and statistical
issues need thoughtful consideration.
In 2005, the worldwide first placebo-controlled ran-
domized trial designed specifically to investigate the
influence of lithium on suicidal behavior was conducted
and published in 2008 by Lauterbach et al. [16]. Survival
analysis showed no significant difference in suicidal acts
between lithium and placebo-treated individuals (adjusted
hazard ratio 0.517; 95 % CI 0.18–1.43); however, post hoc
analysis revealed that all completed suicides had occurred
in the placebo group accounting for a significant differencein incidence rates (P = 0.049). Within a treatment
period of one year, no suicides occurred within the lith-
ium group (n = 84) compared to three suicides within
the placebo group (n = 83). No significant differences
were found in terms of suicide attempts (seven suicide
attempts each in the placebo and lithium group). To
date, no study has investigated how fast this anti-
suicidal effect appears. It is unclear where in the course
of treatment this effect arises.
The primary aim of the present study is to determine
whether lithium exerts an anti-suicidal effect through a
decrease in suicidal thoughts and/or behavior within the
first 5 weeks of treatment. The secondary aim of the
study is to determine whether lithium influences suicidal
thoughts and/or behavior through the indirect path of
improving depressive symptoms, anxiety or impulsivity.
Methods/Design
The present study is a multi-center, 4 year, randomized
placebo-controlled double-blind trial. Patients with uni-
polar or bipolar disorder suffering from a major depres-
sive episode with suicidal thoughts and/or behavior
according to DSM IV criteria will be randomly allocated
to lithium therapy plus treatment as usual versus pla-
cebo treatment plus treatment as usual. The hypothesis
to be tested is that lithium treatment plus treatment as
usual leads to a significant reduction of suicidal thoughts
and/or behavior compared to placebo therapy plus
treatment as usual within 5 weeks of treatment. The pri-
mary end point of this study is the change in Sheehan
Suicidality Tracking Scale (S-STS, [17]) between the be-
ginning of treatment and after a treatment episode of
5 weeks. Further endpoint in this study are changes in
the Columbia-Suicide Severity Rating Scale (C-SSRS,
[18]), the Montgomery Asberg Depression Rating Scale
(MADRS, [19]), the Hamilton Anxiety Scale (HAM-A,
[20]), the Clinical Global Impression Scale (CGI, [21])
and the Barratt Impulsivity Scale (BIS, [22]) from initial
treatment to 5 weeks post treatment. A comparison of
total scores in the C-SSRS, MADRS, HAM-A and the
Young Mania Rating Scale (YMRS, [23]) within the par-
ticipating centers will be conducted. In addition, the
number and dosage of concurrent medication and num-
ber of psychotherapy hours will be explored as second-
ary endpoint. Weekly changes in the C-SSRS, MADRS,
HAM-A and YMRS within the observation period and
percentage of days where the S-STS Scale score equals
zero will be reported. Two-hundred and fifty-four pa-
tients will be included with, thereof 127 in each treat-
ment group. Recruitment started on October first, 2013
and will end on September 30th, 2017. Treatment in-
cludes 5 weeks of treatment plus 1 week of follow-up.
For a detailed description of the inclusion and exclusion
criteria, please see Table 1.
Table 1 In-and exclusion criteria
Inclusion criteria Exclusion criteria
- Male and female patients at least 18 years of age and older
- Presenting with a depressive episode (MDE, uni/bipolar), moderate
to severe according to DSM IV criteria
- Admitted as an inpatient
- Suicidal thoughts and/or behavior defined by a score≥ 8 in the
S-STS scale and a score≥ 20 in the MADRS Scale at time of screening
and baseline
- Written informed consent
- Pre-treatment with lithium within the last six months before inclusion
in the study
- Patients after compulsory hospitalization or patients unable to understand
the study protocol
- Diagnosis of antisocial and/or Borderline personality disorder, alcohol and
drug dependency (positive drug screening)
- Contraindication following drug approval such as severe heart failure
(arrhythmias), severe renal dysfunction, Addison’s disease and others
- History of hypersensitivity towards components of trial medication
- Pregnant or lactating women, women attempting to get pregnant,
and women not practicing a reliable method of contraception
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Patients will be recruited from six psychiatric hospitals
(Dresden University Clinic, Dresden Neustadt, Berlin,
Bochum, Frankfurt, Göttingen) in Germany. Specifically,
patients will be recruited upon admission. All patients
meeting inclusion criteria will be informed about the
study by one of the investigators. Following informed
written consent, randomization will be conducted by a
central block design, allocating the participant to one of
the two treatment groups. Figure 1 shows the trial time-
line.
Intervention/Course
Patients allocated to the lithium treatment group will re-
ceive an oral starting dose of 295 mg lithium carbonate
on the first day, increased to 885 mg on the second day,
increasing the dosage to serum concentrations between
0,6 and 1,0 mmol/l regularly given twice daily for a total
of 5 weeks. Lithium levels will be measured 3 days after
first intake and every 3 days after dose changes. Those
being allocated to the placebo group will receive the
placebo with a virtual concentration level between 0,6
and 1,0 mmol/l also for 5 weeks. The psychiatrist whoFig. 1 Trial flowdispenses and recommends dose adjustments of both
lithium and placebo will be different from the patient’s
treating psychiatrist and will be blind to the patients
study group. Both groups will receive treatment as usual
for their depressive symptoms. The average hospital stay
for patients with depression and suicidal thoughts and/or
behavior in Germany is about 4 weeks. If the patient is dis-
charged from the hospital before the end of the study, the
patient will continue in the study as an outpatient using
the same procedure.
In total there will be nine study visits. The screening
visit (V1, day −3 to 0) will involve confirmation of eligi-
bility, informed written consent, anamnesis, an ECG, a
physical exam, and a blood sample for lithium level
measurement. Afterwards (up to 3 days later) a baseline
screening visit (V2) at day 0 will occur. At the baseline
visit, eligibility will be re-confirmed in addition to
randomization and beginning of treatment in the even-
ing. Three days after the baseline visit (V2), weekly visits
(V3–V7) will occur involving psychometric testing,
examination of vital signs and concurrent medication.
Any adverse events as well as lithium levels will be care-
fully documented at each visit. The end of treatment will
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week following visit 8 will be the final follow-up visit.
This visit will involve safety measurements such as vital
signs, ECG and a blood sample.
Assessments
Clinician administered scales
The Mini International Neuropsychiatric Interview
(MINI, [24]) as well as the structured clinical interview
for DSM-IV axis II personality disorders (SKID II, [25])
will be used for diagnosis. To assess suicidal thoughts
and/or behavior, the Sheehan Suicidality Tracking Scale
(S-STS) is used, both as clinician and self-reported. The
S-STS scale was selected because it maps directly to the
Columbia Classification Algorithm of Suicide Assessment
(C-CASA) coding system, endorsed by the FDA. The
S-STS evolved from the Suicidality Module of the
MINI Structured Diagnostic Interview for DSM-IV
and is a prospective self or clinician report scale.
The eight item scale assesses treatment-emergent suicidal
ideations and treatment-emergent suicidal behaviors.
Each item of the S-STS is scored on a 5-point Likert scale
(0 = not at all, 1 = a little, 2 = moderately, 3 = very, and
4 = extremely) and it takes approximately 1 to 2 min to
complete. Data from the Sheehan-STS can be analyzed
as individual item scores, suicidal ideation subscale
score, suicidal behavior subscale score, and total score.
As suicidal thoughts and/or behavior are primary out-
comes in this study we also included the Columbia-
Suicide Severity Rating Scale (C-SSRS) which has
demonstrated good convergent and divergent validity
with other multi-informant suicidal ideation and behav-
ior scales and demonstrates high sensitivity and specifi-
city for suicidal behavior classifications. The C-SSRS
distinguishes between the domains of suicidal ideation
and suicidal behavior. Four constructs are measured.
The first is the severity of ideation, which is rated on
a 5-point ordinal scale in which 1 = wish to be dead,
2 = nonspecific active suicidal thoughts, 3 = suicidal
thoughts with methods, 4 = suicidal intent, and 5 = suicidal
intent with plan. The second is the intensity of ideation
subscale, which comprises 5 items, each rated on a 5-point
ordinal scale: frequency, duration, controllability, deter-
rents, and reason for ideation. The third is the behavior
subscale, which is rated on a nominal scale that in-
cludes actual, aborted, and interrupted attempts; pre-
paratory behavior; and non-suicidal self-injurious
behavior. The fourth subscale describes lethality, con-
taining the assessment of actual attempts and actual
lethality. It is rated on a 6-point ordinal scale, and if
actual lethality is zero, potential lethality of attempts
is rated on a 3-point ordinal scale. The C-SSRS is fre-
quently recommended by various international agencies
such as the FDA or WHO.The Montgomery Asberg Depression Rating Scale
(MADRS) and the Hamilton Anxiety Rating Scale
(HAM-A) assess depressive and anxiety symptoms.
Symptom severity, treatment response and the efficacy of
treatment are measured using the Clinical Global impres-
sion scale (CGI).
Patient administered scales
To investigate whether the psychological construct of
impulsivity is associated with suicidality, the Barratt
Impulsiveness Scale (BIS) will be applied at weekly inter-
vals during the study. The BIS is a widely used measure
of impulsiveness and includes 30 items that are scored to
yield six first-order factors (attention, motor, self-control,
cognitive complexity, perseverance and cognitive instability
impulsiveness) and three second-order factors (attentional,
motor, and non-planning impulsiveness). The patients will
be also asked to fill out the S-STS as a self-rating instru-
ment on a daily basis.
Power analysis and sample size calculation
A comparable study published by Khan et al. [26] of a 6-
week double-blind trial in 40 patients found a score
reduction of 4.8 (SD = 5.1) in the clinician administered
S-STS in the placebo group, while a score reduction of
6.7 (SD = 5.8) was found among the lithium group The
assumption that all lithium patients achieve a thera-
peutic serum-level in the current study seems to be rea-
sonable due to the considerable higher lithium dose in
comparison with the Khan et al. study. Therefore, these
values have been used as estimates for the expected
group difference in this study.
With an alpha level of 0.05, and statistical power of
0.8, sample size estimation for a two-sided t-test with
unequal variances results in a required number of 131
patients per group. Nevertheless, a t-test has considerably
less power than an analysis of covariance (ANCOVA),
which will be used in this analysis. Borm et al. [27] showed
for sample size n and a baseline-follow-up correlation
rho, that an ANCOVA with (1-rho^2)*n subjects has
the same power as the corresponding t-test. There is
no published data on test-retest correlations of the
S-STS to our knowledge; however, a recalculation of data
from the “Basis-Studie Kompetenznetz Depression” [28]
with 1014 naturalistically treated depressed patients
showed correlations from 0.36 to 0.54 for the self-
report S-STS between baseline and week 8. Therefore, a
conservative assumption of 0.3 for the expected correl-
ation was chosen, which yields a number of 120 patients
per group. These patients will form the modified
Intention to Treat (ITT) sample including all patients
who will be randomized and not discontinue from the
study before any efficacy measurement. A rate of ap-
proximately 5 % of randomized patients dropping out for
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which results in 127 patients needed to be randomized
per group. Therefore, 508 patients will be required to be
screened assuming a rate of 50 % of screened patients ful-
filling the inclusion criteria. We are expecting good
adherence to the intervention as this will not result in
major side effects. However, we anticipate that there will
be about 5 % loss to follow-up, and this is accounted for
in the sample size estimation.
As the study is a multi-center trial, randomization will
be carried out by a centralized computer randomization
directly after screening and obtainment of written in-
formed consent at visit 2 (baseline). Study participants
and the treating mental health team on the inpatient
unit will be blinded for group assignment. A rater-
training (including assessment of inter-rater reliability)
will be provided before the study commences to minimize
differences between centers.
Statistical analysis
Descriptive statistics using proportions, means and
standard deviations will be reported where appropriate.
All efficacy outcome measures will be analyzed on an
intent-to-treat (last observation carried forward) basis
and study completer basis. Results will be presented with
95 % confidence intervals where applicable. Proportions
of adverse events will be summarized. All statistical tests
will be two-sided using an alpha level of 0.05. Analyses
will be adjusted for age and gender when there is a sig-
nificant difference between the groups at baseline.
Primary outcome measures
An analysis of covariance (ANCOVA) model will be
used to compare the final clinician administered S-STS
scores between the groups, including the initial score as
a covariate.
Secondary outcome measures
ANCOVA models will be also used for continuous vari-
ables, including the initial S-STS score as a covariate.
The number of days with a patient-rated S-STS score of
0 will be calculated for each patient, and compared
between the groups. Because this outcome measure is a
count variable, Poisson regression will be applied. Cu-
mulative regression models will be applied for the
comparison between groups for the BIS, CGI and the
C-SSRS-items concerning severity and intensity of
ideation. For the analysis of longitudinal data, (i.e. the mod-
elling of weekly score change), mixed regression models
will be used.
Data and safety management
Pre-trial visits will be performed at all sites by the coord-
ination Centre of Clinical Trials (KKS) Dresden toevaluate the qualification of the sites, and the recruit-
ment of the necessary number of patients. To ensure the
study is conducted in accordance with the protocol and
Good Clinical Practice (GCP), monitoring will be per-
formed by experienced personnel from the KKS Dresden
at each site in appointed time intervals (per site, once at
initiation of the study, once after the first subject was
randomized, once when the last subject completed the
study), for a total of 11 regular monitoring visits per site.
The monitoring process will be performed according
to the SOPs of the sponsor of this trial, the Dresden
University of Technology. The monitor will check com-
pleteness and plausibility of the data and will align the
study data to the original data (Source Data Verification).
This will be accomplished by accessing the subject’s
charts. As part of the consent, subjects give permission
for study personnel to access their medical charts. The
monitor will ensure the basic claim of integrity and
protection of the subject’s privacy. All trials with the
Dresden University of Technology will be audited. All
assessed data will be recorded in the eCRFs with an
audit trail by authorized personnel. A list of signs and
identification codes of all personnel that will enter data
into the CRFs will be stored in the Trial Master File.
Corrections are only allowed to be processed by these
persons. All study data will be stored for 10 years and
will be destroyed afterwards.
This trial will be supervised by a scientific advisory
board including members experienced in assuring data
quality and safety (DSMB). These members have super-
vised the development of this protocol and will supervise
the progress of the trial, including decision making on
whether to perform interim analyses or modify/stop the
trial in case of unforeseeable problems. The members of
this board are completely independent of the coordinat-
ing investigators and the medical institution involved. As
per protocol, all serious adverse events and reactions will
be documented by the investigators, and due to German
Drug law, evaluated and sent to the sponsor, or if neces-
sary to the regulatory authority.
Ethical considerations
An extensive number of patients with depression have
suicidal thoughts and/or behavior during their acute epi-
sodes of illness. All patients will receive TAU. Because of
the long history of lithium in the treatment of mood dis-
orders with well-known (side) effects, the risks associ-
ated with lithium treatment in the proposed study
protocol are considered low, especially as this is only a
5-week trial. The potential benefits of this trial clearly
outweigh the potential risks associated with lithium
treatment. Finally, it has been shown that patients at
high risk for suicide can safely be included in clinical tri-
als such as this one if proper precautions are followed.
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premarket assessments of the risks and benefits of medi-
cations related to suicidal ideation, suicidal behavior, and
suicide in this population [29].
The study has been approved by the Ethics Committee
in Dresden (coordinating centre) on August, 23th
2013 (EUDRACT number 2013-000970–31) and was
also approved for all participating centres (Dresden
University Clinic, Dresden Neustadt, Berlin, Bochum,
Frankfurt, Göttingen).
Discussion
Lithium has shown to have suicide-preventing effects in
patients with affective disorders over the long-term
course. No study has investigated whether this effect
occurs at the beginning of treatment or develops after
months of ongoing lithium therapy. The results of this
study should indicate whether lithium leads to a de-
crease in suicidal thoughts and/or behavior within the
beginning of the treatment (5 weeks).
There is a critical need to identify treatments that will
acutely decrease suicidal ideation and/or behavior.
Lithium therapy is widely available and inexpensive. The
potential benefits of lithium therapy on acute suicidal
ideation and/or behavior in patients with affective disor-
ders need to be clarified.
In designing this study, we aimed to be as close as
possible to a real-world clinical setting. The recruiting
centers are a mix of university and community based
psychiatric hospitals which represents a broad spectrum
of patients with affective disorders. We are aware that
the TAU condition may cause additional heterogeneity,
as this can vary from center to center, or even within
one center through different approaches of the treating
psychiatrists.
This proposed study has several limitations: i) suicidal
patients are generally excluded from clinical (especially
pharmacological) trials. Therefore special attention and
care is needed to minimize the risk in this high-risk
population while undergoing a clinical trial. ii) Patients
with acute suicidal crisis admitted to the hospital and
treated with combined pharmacological and psycho-
logical treatments sometimes show a sudden improve-
ment in terms of their suicidality, especially in those
who were intoxicated at the time of admission. In the lit-
erature this effect is well-described as a suicide-cathartic
effect after a suicide attempt [30]). Suicidality fluctuates
in patients with depressive symptoms from the day of
admission to a few days later when they usually are be-
ing informed about the study. As Davis et al. [31] stated,
interpersonal support (attention from loved ones, and
benefits from therapy) may be a mechanism by which a
patient experiences immediate relief, and therefore
decreased suicidal ideation/behavior. iii) Currently, noapproved medication exists to treat suicidality. Patients
may express concerns that they will be receiving a medi-
cation that is not approved for their specific symptoms
and may refuse to participate.
Despite these challenges we anticipate that the results
of this study (coming from a real world setting), will
provide novel information that could lead to better
pharmacological treatment and prevention strategies for
patients with an acute major depressive episode with
suicidal ideation and/or behavior, and may help reduce
the immense individual distress for families in which a
member is suffering from depression with suicidality.
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